hotspot -WSS

hotspot

author：comprehensive 2025-09-30 18:16:26 - browse：86728

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Prime Medicine, Myeloid Therapeutics clash over genome

leisure time

explore

WSS

What STAT readers think about the FDA and patient advocacy

Life sciences deals on track to hit lowest point since 2017

Keeping primary care docs in field isn't impossible, says AAFP CEO

Virtual care provider acquires bankrupt Pear's prescription apps

Keeping primary care docs in field isn't impossible, says AAFP CEO

Medicare to cover more brain scans related to Alzheimer’s drugs

hotspot

hotspot

Wikipedia

Virginia high school admissions case could be legal follow

Christmas in the PICU brings some surprising joy

New air purifier tech could be key to improving indoor air quality

Medicare to cover more brain scans related to Alzheimer’s drugs

23andMe had bad news about my health. I wish a person had delivered it

Violet CEO on training clinicians to promote more inclusive care

How to save PrEP access — and even expand it

Researchers CRISPR chickens in bid to protect them from bird flu

Walensky prepares to leave CDC — and Congress — behind

Wellcome Trust names Røttingen as its new CEO

Wikipedia

European regulators recommend Amylyx's ALS drug be rejected

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Virtual care provider acquires bankrupt Pear's prescription apps

Nick Jonas talks about managing diabetes along with his career

How clinical AI models' predictive power can degrade over time

Humana CEO Bruce Broussard to step down in 2024

leisure time

explore

Wikipedia

knowledge